Merck bets $700M on an antibody drug’s potential in immune diseases
Bio Pharma Dive
AUGUST 9, 2024
The deal hands Merck a cancer medicine already in human testing, but that the company sees as a potential treatment for autoimmune conditions, too.
Bristol Myers pays Agenus $200M for drug aimed at top immunotherapy target
Bio Pharma Dive
MAY 18, 2021
The pharma acquired rights to an experimental antibody medicine that blocks a protein, called TIGIT, that's become a focus for several cancer drugmakers.
Protein 
333
333 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Merck, facing threat to Keytruda, buys into new kind of cancer immunotherapy
Bio Pharma Dive
NOVEMBER 14, 2024
The company is paying China-based biotech LaNova Medicines $588 million for the type of dual-pronged antibody drug that recently bested Keytruda in a clinical trial.
Clinical Trials 299
299 
Dantari emerges with a new way to make cancer drug conjugates
Bio Pharma Dive
DECEMBER 8, 2022
As the success of drugs like Enhertu catalyzes new investment in antibody-drug conjugates, the California startup is launching with plans to develop more potent versions of the targeted cancer medicines.
Drugs 323
323 
J&J wins approval of new kind of multiple myeloma drug
Bio Pharma Dive
OCTOBER 26, 2022
The treatment, which will be sold as Tecvayli, is the first bispecific antibody cleared for the disease. It joins a group of medicines on market that target a protein called BCMA.
Protein 284
284 
Sanofi, Regeneron surge as Dupixent scores in COPD trial
Bio Pharma Dive
MARCH 23, 2023
The two companies gained billions of dollars in market value after their antibody drug succeeded against a disease that’s been difficult to treat with biologic medicines.
Antibody 280
280 
Seagen, Genmab win speedy FDA approval for cervical cancer drug
Bio Pharma Dive
SEPTEMBER 21, 2021
Tivdak, a type of drug known as an antibody-drug conjugate, is the fourth approved medicine for Seagen and its third to reach market since December 2019.
FDA Approval 279
279 
Navigator gains $100m in Series A funding for antibody therapeutics
Pharmaceutical Technology
AUGUST 28, 2024
Navigator Medicines has secured $100m in a Series A financing round with the aim of advancing bispecific antibody therapeutics.
Antibody 130
130 
IgY antibody technology against SARS-CoV-2 unveiled
Pharma Mirror
JANUARY 29, 2022
An IgY neutralizing antibody, which is claimed to inhibit the activity of SARS-CoV-2, the novel coronavirus that causes COVID-19, by over 99 percent, was launched in Shenzhen on Monday, according to Shenzhen Special Zone Daily. Shenzhen) and a local precision medicine research institute.
Antibody 130
130 
Lilly to buy Versanis, adding to obesity drug pipeline
Bio Pharma Dive
JULY 14, 2023
billion to acquire the private biotech and its experimental antibody, which Lilly plans to pair with its own weight loss medicines. The pharma will pay up to $1.9
Antibody 246
246 
Disc and Mabwell sign deal for licence to antibodies portfolio
Pharmaceutical Technology
JANUARY 23, 2023
Disc Medicine has entered an exclusive licence agreement with Mabwell Therapeutics for the latter’s new Anti-TMPRSS6 (Transmembrane Serine Protease 6, also known as Matriptase-2) monoclonal antibodies to modulate iron homeostasis. development and commercial milestones. development and commercial milestones.
Antibody 130
130 
Datroway’s Approval in Breast Cancer Solidifies Daiichi Sankyo’s Leadership in ADCs
XTalks
JANUARY 21, 2025
The FDA has approved Datroway (datopotamab deruxtecan-dlnk), a TROP2-directed antibody-drug conjugate (ADC) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer, developed through a global collaboration between Daiichi Sankyo and AstraZeneca. Datroway leverages DXd technology to precisely target cancer cells.
Antibody 105
105 
Innovation in immuno-oncology: Leading companies in tumour antibody serum compositions
Pharmaceutical Technology
MARCH 9, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Tumour antibody serum compositions. The production of antibodies in response to proteins expressed during cancer development serves as a biomarker.
Antibody 147
147 
Key trial test begins for plasma-based COVID-19 therapy from Takeda, CSL
Bio Pharma Dive
OCTOBER 9, 2020
The medicine, a concentrated infusion of blood antibodies, is different than the convalescent plasma that was recently cleared for emergency use by the FDA.
Antibody 234
234 
WHO grants emergency use listing to SK bioscience’s SKYCovione
Pharmaceutical Technology
JUNE 20, 2023
It was developed in collaboration with the Institute for Protein Design (IPD) at the University of Washington School of Medicine, with funding support from the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations (CEPI).
Vaccination 363
363 
Sanofi pays IGM $150M, continuing search for better antibody drugs
Bio Pharma Dive
MARCH 29, 2022
The French pharmaceutical giant has inked its third antibody-focused deal since December, this time betting on a Californian biotech trying to pioneer a new class of medicines.
Antibody 130
130 
Covid evolution wipes out another antibody treatment, threatening the country’s medicine cabinet
STAT News
NOVEMBER 30, 2022
The Food and Drug Administration on Wednesday ended its emergency authorization for the only remaining Covid-19 antibody therapy cleared for use, saying variants that render it ineffective are now dominant in the United States. have been growing in prevalence. Read the rest…
Antibody 111
111 
Biocytogen and ADC to evaluate antibodies for three cancer targets
Pharmaceutical Technology
NOVEMBER 27, 2022
Biocytogen Pharmaceuticals and ADC Therapeutics have signed an assessment and option agreement for evaluating antibodies against three tumour targets. Under the deal, ADC Therapeutics will receive a licence from Biocytogen to evaluate the latter’s antibodies against the targets.
Antibody 130
130 
Gemini enters business combination deal with Disc Medicine
Pharmaceutical Technology
AUGUST 11, 2022
Gemini Therapeutics has signed a definitive agreement to merge with Disc Medicine in an all-stock deal to create a clinical-stage biopharmaceutical company. The merged company is expected to be named Disc Medicine, which will have corporate headquarters in Watertown, Massachusetts, US. To back the merger, Disc raised funds worth $53.5m
Medicine 147
147 
Sanofi unveils global health brand for medicines supply
Pharmaceutical Technology
JULY 5, 2022
Through the Impact brand, which comprises insulin, glibenclamide and oxaliplatin among others, the company will supply its 30 medicines in 40 lower-income countries in the world. The post Sanofi unveils global health brand for medicines supply appeared first on Pharmaceutical Technology.
Branding 147
147 
A biotech startup with big-name backers aims to create new cancer medicines
Bio Pharma Dive
APRIL 14, 2023
Newly launched TORL BioTherapeutics wants to develop a variety of antibody drugs, and comes equipped with $158 million as well as a close partnership with the lab of pioneering breast cancer researcher Dennis Sloman.
Medicine 171
171 
Gilead partners with MacroGenics for bispecific antibody development
Pharmaceutical Technology
OCTOBER 18, 2022
Gilead Sciences has entered an exclusive option and partnership agreement with MacroGenics for developing bispecific antibodies. MGD024 is an investigational bispecific antibody that attaches to CD123 and CD3. The post Gilead partners with MacroGenics for bispecific antibody development appeared first on Pharmaceutical Technology.
Antibody 130
130 
Regeneron’s antibody cocktail active against coronavirus, cuts symptoms
pharmaphorum
SEPTEMBER 30, 2020
Regeneron’s antibody cocktail seems to reduce levels of coronavirus and improve symptoms in patients, according to early test results. This first data comes from a descriptive analysis from the seamless phase 1/2/3 trial that Regeneron hopes will hurry the medicine dubbed REGN-COV2 to market.
Antibody 135
135 
Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld
pharmaphorum
AUGUST 12, 2022
Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld. One group of Chinese researchers has reported however that BA.4
Antibody 145
145 
Alentis Therapeutics raises funds to develop medicines for CLAUDIN-1
Pharmaceutical Technology
APRIL 13, 2023
Clinical-stage biopharmaceutical firm Alentis Therapeutics has raised $105m in a Series C financing round for advancing transformational medicines targeting the CLAUDIN-1 protein. ALE.F02 is being developed for the treatment of advanced kidney, lung and liver fibrosis while ALE.C04 is a potential treatment to target CLDN1-positive tumours.
Medicine 130
130 
Malaysia approves additional indication for Astrazeneca’s Evusheld
Pharmaceutical Technology
APRIL 10, 2023
Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061). The long-acting antibodies are obtained from B-cells that are donated by convalescent patients following Covid-19 infection.
Immune Response 264
264 
SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine
Pharmaceutical Technology
MAY 30, 2023
SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. It was granted based on data from the Phase III study, which demonstrated that the vaccine induced neutralising antibodies against the SARS-CoV-2 original strain.
Vaccine 298
298 
Sterling Pharma Solutions Granted MIA (IMP) License by MHRA for cGMP Antibody-Drug Conjugate Manufacturing at its Facility in Deeside, UK
Pharma Mirror
APRIL 18, 2023
Dudley, UK, April 18th 2023: Sterling Pharma Solutions, a global contract development and manufacturing organisation, today announced that it has been granted a Manufacturer’s Authorisation for Investigational Medicinal Products from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA).
Licensing 130
130 
LegoChem, Amgen partner to develop antibody drug conjugates
Pharmaceutical Technology
DECEMBER 26, 2022
LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The post LegoChem, Amgen partner to develop antibody drug conjugates appeared first on Pharmaceutical Technology.
Antibody 130
130 
Monoclonal antibody treatment for malaria shows encouraging results
STAT News
AUGUST 3, 2022
An experimental antibody treatment prevented malaria in the majority of participants in a small but important new study , providing a measure of hope in the effort to lower the burden of the disease worldwide. Read the rest…
Antibody 105
105 
Feinstein Institutes researchers discover new protein for sepsis treatment
Pharmaceutical Technology
FEBRUARY 6, 2023
It explores the monoclonal antibody detection that may work against procathepsin-L (pCTS-L), a pro-inflammatory protein mediator, as the potential remedy. These anti-pCTS-L monoclonal antibodies may help in providing effective treatments for human sepsis as well as other infectious diseases, such as Covid-19.
Protein 263
263 
Innovation in immuno-oncology: Leading companies in monoclonal antibody conjugates for cancer treatment
Pharmaceutical Technology
MAY 8, 2023
In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Monoclonal antibody conjugates for cancer treatment.
Antibody 130
130 
China’s NMPA clears Transcenta’s IND for solid tumour treatment
Pharmaceutical Technology
JANUARY 4, 2023
TST003 is a first-in-class Gremlin1 targeting humanised monoclonal antibody. In the syngeneic tumour model, the monoclonal antibody has also improved the checkpoint inhibitor’s anti-tumour activity.
Antibody 242
242 
AstraZeneca buys into startup RQ Bio’s COVID antibodies
pharmaphorum
MAY 18, 2022
Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and immunosuppressed people from COVID-19. ” The post AstraZeneca buys into startup RQ Bio’s COVID antibodies appeared first on.
Antibody 98
98 
STAT+: ‘Practice changing’: Antibody treatment benefits leukemia patients receiving bone marrow transplant
STAT News
FEBRUARY 21, 2023
An experimental antibody that delivers lethal radiation directly to the bone marrow improved the outcomes of stem cell transplants for older patients with relapsed leukemia — and may change the way transplant medicine is practiced.
Antibody 105
105 
J&J to acquire ADC drug developer Ambrx for $2B
Bio Pharma Dive
JANUARY 8, 2024
The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.
Drugs 183
183 
Genmab buys ProfoundBio for $1.8B, adding to ADC dealmaking flurry
Bio Pharma Dive
APRIL 3, 2024
The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.
Antibody 171
171 
Monoclonal antibodies: GSK and Vir to seek US approval for their COVID-19 candidate, EMA starts rolling review of Lilly's medicines
BioPharma Reporter
MARCH 11, 2021
GSK and its partner, Vir Biotechnology, report that their jointly developed monoclonal antibody, VIR-7831, reduces hospitalization and risk of death in early treatment of adults with COVID-19.
Antibody 105
105 
Sanofi, AstraZeneca win EMA support for RSV drug in babies
Bio Pharma Dive
SEPTEMBER 16, 2022
If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants.
Antibody 177
177 
At ESMO, three studies show promise of antibody-drug conjugates in breast cancer
pharmaphorum
MAY 30, 2022
pharmaphorum sat down with Sunil Verma, global head of oncology, medical, at AstraZeneca, to discuss three studies that were presented at the show, which demonstrate a few of the ways oncology is advancing through precision medicine and targeted therapies. That antibody-drug conjugate then docks on the cancer cell receptor.
Antibody 116
116 
Let's personalize your content